SCHEMBL19492870

SCHEMBL19492870

COc1c(C(=O)O)cnc2c(Br)c(C)nn12

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ KDM4E B2RXH2 7/20 0.40
▸ ALDH1A1 P00352 6/20 0.40
▸ MAPT P10636 5/20 0.38
▸ LMNA P02545 2/20 0.38
▸ POLB P06746 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ KMT2A Q03164 1/20 0.35
▸ ELANE P08246 1/20 0.35
▸ MCL1 Q07820 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19492634 0.84 KDM4E (0.51) KDM4EALDH1A1MAPTLMNAPOLB
SCHEMBL28630088 0.81 KDM4E (0.43) TDP1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL28619853 0.80 KDM4E (0.42) TDP1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL19492615 0.78 KDM4E (0.40) TDP1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL28634209 0.78 HPGD (0.43) TDP1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL19464294 0.78 KDM4E (0.40) TDP1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL19492503 0.77 ALDH1A1 (0.47) KDM4EALDH1A1MAPTLMNAPOLB
SCHEMBL19464269 0.77 ALDH1A1 (0.40) TDP1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL19463979 0.76 KEAP1 (0.40) TDP1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL19463509 0.74 TP53 (0.49) KDM4EALDH1A1MAPTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442974-B1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-06-07 — — EP disclosed
EP-3442974-B1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-06-07 — — EP disclosed
CN-109071545-B Novel pyrazolopyrimidine derivatives 拜耳动物保健有限责任公司 2021-08-03 — — CN disclosed
US-11001590-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-05-11 — — US disclosed
US-11001590-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-05-11 — — US disclosed
US-10934301-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-03-02 — — US disclosed
US-10934301-B2 Pyrazolopyrimidine derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-03-02 — — US disclosed
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-09-24 — — US disclosed
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-09-24 — — US disclosed
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-07-30 — — US disclosed
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2020-07-30 — — US disclosed
US-10604525-B2 Pyrazolopyrimidine derivatives BAYAL ANIMAL HEALTH GMBH (DE) 2020-03-31 — — US disclosed
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-03-07 — — US disclosed
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2019-03-07 — — US disclosed
WO-2017178416-A1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2017-10-19 — — WO disclosed
US-9408927-B2 Contrast agents for applications including perfusion imaging LANTHEUS MEDICAL IMAGING, INC. (US) 2016-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604525-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 TDP1 1732/4885L3MBTL1 3187/4885KDM4E 1438/4885
US-11001590-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 TDP1 1742/4885L3MBTL1 3191/4885KDM4E 1445/4885
US-20190071447-A1 PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 TDP1 1732/4885L3MBTL1 3187/4885KDM4E 1438/4885
US-20200239482-A1 PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 TDP1 1742/4885L3MBTL1 3191/4885KDM4E 1445/4885
US-10934301-B2 Pyrazolopyrimidine derivatives P2RX5, RECQL, P2RX1 TDP1 1742/4885L3MBTL1 3191/4885KDM4E 1445/4885
US-20200299299-A1 NEW PYRAZOLOPYRIMIDINE DERIVATIVES P2RX5, RECQL, P2RX1 TDP1 1668/4885L3MBTL1 3856/4885KDM4E 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback